Braveheart Bio, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Braveheart Bio, Inc. (BRVE) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 60.54 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-09-08.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-09-08
- 2026-06-30: Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month 60.54M shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month |
|---|---|
| 2026-06-30 | 60.54M shares 10-Q · filed 2026-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |